Table 7 Summary of recent studies on circRNAs as diagnostic markers in AML
From: The emerging functions and clinical implications of circRNAs in acute myeloid leukaemia
CircRNAs | Cohort size | Dysregulation | Sample source | AUC | Sensitivity | Specificity | References |
|---|---|---|---|---|---|---|---|
Hsa_circ_0004277 | Normal (n = 8); ND AML (n = 67) | ↓ in AML | BM | 0.957 | NR | NR | [70] |
Circ-ANXA2 (Hsa_circ_0035559) | Normal (n = 50); AML (n = 130) | ↑ in AML | BM | 0.832 | NR | NR | [74] |
CircZBTB46 (Hsa_circ_103104) | Normal (n = 9); AML (n = 18) | ↑ in AML | BM | 0.969 | NR | NR | [77] |
|  | Normal (n = 25); AML (n = 25) | ↑ in AML | PB | 0.83 | NR | NR | [77] |
Hsa_circ_0044907 | Normal (n = 45); AML (n = 45) | ↑ in AML | BM | 0.9447 | 77.78% | 88.89% | [129] |
CircPLXNB2 (Hsa_circ_0001257) | Normal (n = 15); AML (n = 40) | ↑ in AML | BM | 0.8525 | NR | NR | [138] |
Hsa_circ_0001947 | Normal (n = 15); ND AML (n = 59) | ↓ in AML | BM | 0.8911 | 93.33% | 73.33% | [152] |
Circ-ANAPC7 | IDA Controls (n = 80); ND AML (n = 144) | ↑ in AML | BM | 0.915 | NR | NR | [173] |
Circ-PVT1 | Normal (n = 30); AML (n = 68) | ↑ in AML | BM | 0.92 | 72.10% | 96.70% | [174] |
|  | Non-proliferative haematological disorder controls (n = 30); AML (n = 68) | ↑ in AML | BM | 0.814 | 72.10% | 90.00% | [174] |
|  | Non-CR (n = 19); CR (n = 49) | ↑ in non-CR | BM | 0.712 | 57.10% | 84.20% | [174] |
Hsa_circ_0079480 | Normal (n = 160); AML (n = 236) | ↑ in AML Serum | PB | 0.9342 | NR | NR | [175] |
Circ-Foxo3 | Normal (n = 24); AML (n = 116) | ↓ in AML | BM | 0.633 | 62.10% | 75% | [176] |
Circ_0059706 | Normal (n = 33); AML (n = 100) | ↓ in AML | BM | 0.925 | NR | NR | [177] |